SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma plans to launch 8-10 branded formulations during FY18

05 Jun 2017 Evaluate

In a bid to achieve 20% growth year-on-year, Natco Pharma is planning to launch around 8-10 new products in domestic branded formulations segment during FY18. The Hyderabad-based drug firm is also planning to maintain its leadership position in oncology and gastro hepatology segment during the year as part of its short-term growth plan.

Moreover, the company is looking at gaining traction in the newly launched cardiology and diabetology (CnD) division. The company is also planning to expand its Hepatitis-C product portfolio during the year.

 

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×